Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scynexis Inc (NQ: SCYX )

2.000 +0.440 (+28.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,599,815
Open 1.660
Bid (Size) 2.020 (30)
Ask (Size) 2.100 (50)
Prev. Close 1.560
Today's Range 1.660 - 2.280
52wk Range 1.150 - 5.147
Shares Outstanding 32,656,992
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga

Performance

YTD
+38.89%
+38.89%
1 Month
+29.87%
+29.87%
3 Month
+14.94%
+14.94%
6 Month
-21.57%
-21.57%
1 Year
-60.08%
-60.08%

More News

Read More
Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock
Via Benzinga
SCYNEXIS's Return On Capital Employed Overview
Via Benzinga
Scynexis Looks For Commercial Partner For Its Lead Infection Treatment
Via Benzinga
Scynexis Touts Postive Data For Ibrexafungerp For Vaginal Infections
Via Benzinga
SCYNEXIS: Q1 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Looking Into SCYNEXIS's Return On Capital Employed
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Earnings Scheduled For August 15, 2022
Via Benzinga
SCYNEXIS Shares Climb As FDA Accepts Filing For Vaginal Yeast Infection Candidate Under Priority Review
Via Benzinga
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
Via Benzinga
This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
Earnings Outlook For SCYNEXIS
Via Benzinga
Earnings Scheduled For May 12, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.